ALK and non-small cell lung carcinoma: Targeted therapy based on small molecules has emerged as a promising approach and has substantially improved treatment outcomes for NSCLC patients carrying targetable molecular alterations, including EGFR activating mutations, anaplastic lymphoma kinase (ALK) translocations, c‐ros oncogene 1 (ROS1) translocation,3, 4, 5 and so on.